Simple Summary Neuroblastoma is a pediatric tumor originating from the precursors of
sympathetic nerves. The disease is known for its high heterogeneity. Hence, developing …

Neuroblastoma (NB) is the most frequent solid tumor in pediatric cases, contributing to
around 15% of childhood cancer-related deaths. The wide-ranging genetic, morphological …

Purpose: Chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies are
effective in a subset of patients with solid tumors, but new approaches are needed to …

Novel chimeric antigen receptor (CAR) T-cell approaches are needed to improve
therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid …

Despite the great success that chimeric antigen receptor (CAR) T-cells have had in patients
with B-cell malignancies and multiple myeloma, they continue to have limited efficacy …

High-risk neuroblastoma remains a profound clinical challenge that requires eradication of
neuroblastoma cells from a variety of organ sites, including bone marrow, liver, and CNS, to …

Neuroblastoma, a paediatric malignancy of the peripheral nervous system, displays a wide
range of clinical outcomes, including regression to fatality despite extensive treatment …

Background Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable
remission in patients with B-cell malignancies. However, its efficacy in treating solid tumors …

Results Overexpression of tyrosine hydroxylase (TH), PHOX2B, PRAME, GPC2, B7-H3, and
Survivin is the most typical for NB. Positive expression of MAGEA3, MAGEA1, and NY-ESO …

Chimeric antigen receptor T-cells, known as CAR-T cells, represent a promising
breakthrough in the realm of adoptive cell therapy. These T-cells are genetically engineered …